The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Stoke Therapeutics, Inc(NASDAQ:STOK) 
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary ribonucleic acid therapeutics platform, Targeted Augmentat...
Website: http://www.stoketherapeutics.com
Founded: 2015
IPO Price: $18 (Jun 19, 2019)
Full Time Employees: 56
CEO: Edward M. Kaye
Sector: Healthcare
Industry: Biotechnology
Stoke Therapeutics Days Payable Outstanding ttm (DPO)
Stoke Therapeutics Days Receivable Outstanding ttm (DSO)
Stoke Therapeutics Days Inventory Outstanding ttm (DIO)
Stoke Therapeutics Op Cashflow Per Share ttm
Stoke Therapeutics Free Cashflow Per Share ttm
Stoke Therapeutics Cash Per Share ttm
Stoke Therapeutics P/S ratio ttm
Stoke Therapeutics (GAAP) P/E ratio ttm
Stoke Therapeutics P/B ratio ttm
No extra charts and metrics for this ticker.